Catuxa Prado

Catuxa Prado

Auto-generated profile, based on publicly available information

Catuxa Prado

Neuroscience Innovative Technologies S.L., Neurostech, 33428 Llanera, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LELeticia Esteban-Tejeda
Leticia Esteban-Tejeda
CPCatuxa Prado
Catuxa Prado
BCBelén Cabal
Belén Cabal
JSJesús Sanz
Jesús Sanz
RTRamón Torrecillas
Ramón Torrecillas
JMJosé Serafín Moya
José Serafín Moya
A new family of non-toxic biocides based on low melting point (1250°C) transparent glasses with high content of ZnO (15–40wt%) belonging to the miscibility region of the B2O3-SiO2-Na2O-ZnO system has been developed. These glasses have shown an excellent biocide activity (logarithmic reduction >3) against Gram- (E. coli), Gram+ (S. aureus) and yeast (C. krusei); they are chemically stable in different media (distilled water, sea-like water, LB and DMEN media) as well as biocompatible. The cytotoxicity was evaluated by the Neutral Red Uptake using NIH-3T3 (mouse embryonic fibroblast cells) and the cell viability was >80%. These new glasses can be considered in several and important applications in the field of inorganic non-toxic biocide agents such as medical implants, surgical equipment, protective apparels in hospitals, water purifications systems, food packaging, food storages or textiles.

1 March 2011 in Immunobiology
Verified
Journal Article
Closed access
CPCatuxa Prado
Catuxa Prado
JGJesús Gómez
Jesús Gómez
PLPatricia Lopez
Patricia Lopez
BPBanesa de Paz
Banesa de Paz
CGCarmen Gutiérrez
Carmen Gutiérrez
ASAna Suárez
Ana Suárez

21 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JRJavier Rodríguez-Carrio
Javier Rodríguez-Carrio
BPBanesa De Paz
Banesa De Paz
PLPatricia Lopez
Patricia Lopez
CPCatuxa Prado
Catuxa Prado
MAMercedes Alperi-López
Mercedes Alperi-López
ASAna Suárez
Ana Suárez
IFNα has been largely implicated in the ethiopathogenesis of autoimmune diseases but only recently it has been linked to endothelial damage and accelerated atherosclerosis in autoimmunity. In addition, proinflammatory conditions are supposed to be implicated in the cardiovascular status of these patients. Since a role for IFNα in endothelial damage and impaired Endothelial Progenitor Cell (EPC) number and function has been reported in other diseases, we aimed to evaluate the potential associations of IFNα serum levels on EPC populations and cytokine profiles in Rheumatoid Arthritis (RA) patients. pre-EPC, EPC and mature EPC (mEPC) populations were quantified by flow cytometry analyzing their differential CD34, CD133 and VEGFR2 expression in blood samples from 120 RA patients, 52 healthy controls (HC), and 83 systemic lupus erythematosus (SLE) patients as disease control. Cytokine serum levels were measured by immunoassays and clinical and immunological data, including cardiovascular (CV) events and CV risk factors, were retrospectively obtained by reviewing clinical records. Long-standing, but not recent onset RA patients displayed a significant depletion of all endothelial progenitor populations, unless high IFNα levels were present. In fact, the IFNhigh RA patient group (n = 40, 33%), showed increased EPC levels, comparable to SLE patients. In addition, high IFNα serum levels were associated with higher disease activity (DAS28), presence of autoantibodies, higher levels of IL-1β, IL-6, IL-10 and MIP-1α, lower amounts of TGF-β, and increased mEPC/EPC ratio, thus suggesting higher rates of endothelial damage and an endothelial repair failure. Finally, the relationship between high IFNα levels and occurrence of CV events observed in RA patients seems to support this hypothesis. IFNα serum marker could be used to identify a group of RA patients with increased disease activity, EPC imbalance, enhanced proinflammatory profile and higher cardiovascular risk, probably due, at least in part, to an impaired endothelial repair.

29 June 2012 in Rheumatology
Verified
Journal Article
Open access
PDF file
JRJavier Rodríguez-Carrio
Javier Rodríguez-Carrio
CPCatuxa Prado
Catuxa Prado
BPBanesa de Paz
Banesa de Paz
PLPatricia Lopez
Patricia Lopez
JGJesús Gómez
Jesús Gómez
ASAna Suárez
Ana Suárez
Objective. The aim of this study was to investigate the endothelial progenitor cell population in SLE and early RA patients and its potential relationships with disease features and cytokine serum levels. Methods. Endothelial progenitor cells (EPCs), mature EPCs (mEPCs) and endothelial cells (ECs) were measured in peripheral blood samples from 83 SLE and 85 early RA patients and 39 healthy controls by flow cytometry on the basis of CD34, VEGF receptor 2 and CD133 expression. Serum levels of IL-1β, IL-6, IL-8, IL-17, VEGF-A, IFN-α, TGF-β and GM-CSF were quantified by immunoassays. Clinical and immunological data were obtained by reviewing clinical histories. Results. Circulating EPCs were increased in SLE but not in early RA patients associated with an enhanced CD34+ bone marrow-progenitor cell release but unrelated to disease features. The amount of mEPCs, however, was significantly higher in SLE patients presenting anti-SSA/SSB antibodies and/or malar rash, whereas the presence of specific autoantibodies was associated with EC counts in early RA and SLE patients. As expected, most cytokines tested were altered in both diseases but, interestingly, IFN-α levels, and to a lesser extent IL-6 and IL-1β, were associated with CD133 loss and increased mEPC number, whereas VEGF and TGF-β seem to exert an opposite effect. Conclusion. Our results show that high IFN-α levels and/or the presence of disease-specific antibodies may identify a group of SLE patients with increased mEPC and EC counts, and consequently probably defective endothelial repair, thus supporting their use as surrogate biomarkers of endothelial damage and high cardiovascular risk.

24 March 2012 in Rheumatology
Verified
Journal Article
Open access
PDF file
BPBanesa de Paz
Banesa de Paz
CPCatuxa Prado
Catuxa Prado
MAMercedes Alperi-López
Mercedes Alperi-López
FBFrancisco J. Ballina-García
Francisco J. Ballina-García
JRJavier Rodríguez-Carrio
Javier Rodríguez-Carrio
ASAna Suárez
Ana Suárez
Objectives. To investigate CD25−FOXP3+ cells in RA patients and their possible relationship with disease features and response to glucocorticoids (GCs). Methods. Peripheral blood mononuclear cells were collected from 147 RA patients, 29 healthy controls and 75 SLE patients as disease controls. The proportion of CD4+FOXP3+ cells with negative, low or high CD25 expression and the levels of IL-10-, TNF-α-, IL-17- and IFNγ-producing cells were assessed by flow cytometry. The presence of the high IL-10 genotype (−1082GG), associated with good response to GC, was determined by PCR amplification and hybridization with allele-specific fluorescently labelled probes. Data were related to treatment and clinical parameters. Results. The CD25−FOXP3+ population was significantly increased in RA patients and negatively correlated with DAS-28 and other disease parameters. The IL-10 genotype did not influence the frequency of these cells in controls or the entire RA group; however, GC-treated patient carriers of the high IL-10 genotype presented significantly higher levels of this population in addition to an increased percentage of IL-10-secreting cells and relatively low amounts of TNF-α-, IFN-γ- and IL-17-positive cells. Finally, a prospective study confirmed that genetically high IL-10 producers significantly increase CD25−FOXP3+ cells after 6 months of GC treatment. Conclusion. The present study provides the first evidence of increased CD25−FOXP3+ cells in RA patients, which were associated with disease activity and with GC treatment in carriers of the high IL-10 genotype, suggesting that this population plays a role in the clinical response to prednisone in RA.

12 July 2011 in Rheumatology
Verified
Journal Article
Open access
PDF file
CPCatuxa Prado
Catuxa Prado
BPBanesa de Paz
Banesa de Paz
JGJesús Gómez
Jesús Gómez
PLPatricia Lopez
Patricia Lopez
JRJavier Rodríguez-Carrio
Javier Rodríguez-Carrio
ASAna Suárez
Ana Suárez
Objective. To investigate the relative amounts of Th17 and Th1 cells present in SLE patients and the possible effects of treatments or disease features on these populations. Methods. Peripheral blood mononuclear cells were collected from 75 SLE patients and 19 healthy controls and the proportion of Th17 and Th1 populations were assessed by flow cytometry measuring the amount of IL-17 and IFN-γ-producing cells. Gene expression of signal transducers and activators of transcription 3 (STAT3), STAT4, IL-6R and IL-12R were determined in 30 patients and 8 healthy individuals by real-time RT–PCR. Data were related to clinical and immunological parameters and to the treatment followed during the past 3 months. Results. Th17 cells and the Th17/Th1 ratio were significantly increased in SLE patients treated with glucocorticoids compared with healthy individuals, untreated patients or those under other treatments. No association was detected with clinical parameters, but patients with anti-ENA antibodies also displayed increased Th17 responses. Disease activity (SLEDAI) is associated with the Th17/Th1 index only in glucocorticoid-treated patients. In line with these results, gene expression of STAT3 and IL-6R was up-regulated in patients taking these drugs. Accordingly, we found a positive correlation between the Th17/Th1 ratio and STAT3 levels. Conclusions. The present work provides the first evidence that aberrant Th17/Th1 balance in SLE is linked to the use of glucocorticoids and suggests that the up-regulatory effect of these drugs on the Th17 population could be associated with their ability to increase STAT3 and IL-6R expression. Additionally, anti-ENA positivity could represent a potential biomarker for Th17 bias.